Linzess patent?

See the DrugPatentWatch profile for Linzess

When does the Linzess patent expire?


The primary patent for Linzess (linaclotide) is set to expire in 2029. However, this expiration date can be influenced by various factors, including patent litigation and the potential for new patent filings [1].


What is Linzess used for?


Linzess is a medication prescribed to treat adults with two common gastrointestinal conditions: irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) [2].


What is the mechanism of action for Linzess?


Linzess works by activating guanylate cyclase-C (GC-C) in the intestinal wall. This activation increases the secretion of fluid and electrolytes into the intestines, which helps to soften stool and promote bowel movements [3].


Who manufactures Linzess?


Linzess is jointly developed and marketed by Ironwood Pharmaceuticals and AbbVie [4].


What are the risks associated with Linzess?


The most common side effect reported with Linzess is diarrhea [5]. Patients with severe diarrhea may experience dehydration, electrolyte imbalance, and a drop in blood pressure. It is important for patients to discuss any pre-existing medical conditions with their doctor before starting Linzess [2].


Are there any generic alternatives to Linzess?


As of now, there are no generic versions of Linzess available. The availability of generics is directly tied to patent expiration [1].


What is the patent litigation surrounding Linzess?


Patent challenges can impact the timeline for generic entry. Companies often seek to invalidate existing patents or find ways to launch products before patents expire. Information on specific patent litigation for Linzess can be found on specialized databases like DrugPatentWatch.com [1].


Sources:


[1] DrugPatentWatch.com
[2] Linzess Prescribing Information
[3] AbbVie, Inc. (2023). Linzess [Press release].
[4] Ironwood Pharmaceuticals, Inc. (2023). Linzess [Press release].
[5] Linzess (linaclotide) Side Effects